Acute Blood Loss Anemia Clinical Trial
Official title:
Tranexamic Acid in Revision Total Joint Arthroplasty: A Prospective Randomized Controlled Trial
NCT number | NCT02877381 |
Other study ID # | 15063007 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | April 2016 |
Est. completion date | August 1, 2019 |
Verified date | April 2021 |
Source | Rush University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the optimal dosing regimen and route of administration of tranexamic acid (TXA) [single dose intravenous (IV), double dose intravenous, intravenous + topical, and oral repeated dosing] to minimize post-operative blood loss and transfusion requirements following revision total knee arthroplasty (RTKA).
Status | Completed |
Enrollment | 175 |
Est. completion date | August 1, 2019 |
Est. primary completion date | August 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients scheduled for revision THA or TKA defined as femoral component exchange, acetabulum/tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Exclusion Criteria: - Patients scheduled for a head and liner/poly exchange, known allergy to TXA, acquired disturbances of color vision, refusal of blood products, pre-operative use of anticoagulant therapy within five days before surgery, a history of arterial or venous thrombotic disease (including a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cerebrovascular Accident (CVA), Transient Ischemic Attack (TIA)), pregnancy, breastfeeding, or major co-morbidities (myocardial infarction or stent placement within one year, severe pulmonary disease, renal impairment, or hepatic failure). |
Country | Name | City | State |
---|---|---|---|
United States | Rush University Medical Center | Chicago | Illinois |
United States | New York University Medical Center | New York | New York |
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Rush University Medical Center | Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Post-operative reduction in Hemoglobin | Pre-operative hemoglobin minus the lowest post-operative hemoglobin prior to any transfusion | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | |
Primary | Post-operative reduction in Hematocrit | Pre-operative hematocrit minus the lowest post-operative hematocrit prior to any transfusion | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | |
Primary | Calculated blood loss | Based on predicted blood volume and hemoglobin balance | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | |
Primary | Number of units transfused | per patient | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | |
Primary | Number of Patients Transfused | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | ||
Secondary | Cost-comparison | Cost differences resulted from differences in the blood transfusion rate, length of hospital stay, and management of complications as well as from the cost of the TXA itself | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | |
Secondary | Deep Vein Thrombosis, Pulmonary Embolus, Cerebrovascular accident or Transient ischemic attack | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | ||
Secondary | Return to the OR within 30 days; Re-admission within 30 days; Periprosthetic fracture within 30 days | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery | ||
Secondary | Superficial infection or Deep infection, defined as Synovial White Blood Cell (WBC) count > 4200 WBC/ml or Synovial WBC > 3000 WBC/ml & C-Reactive Protein (CRP) > 10 mg/dl & Erythrocyte Sedimentation Rate (ESR) > 30 mm/hr ; | Post-operative and before discharge from hospital (inpatient), < 30 days from surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05081063 -
Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients
|
Phase 3 | |
Completed |
NCT01370460 -
Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
|
Phase 2 | |
Recruiting |
NCT05292001 -
Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma
|
Phase 4 | |
Withdrawn |
NCT02138175 -
Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective
|
||
Completed |
NCT01683955 -
Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty
|
Phase 1 | |
Terminated |
NCT02762773 -
Effect of Non-Dissection of the Inferior Rectus Sheath on Intraoperative Blood Loss
|
N/A |